PTHL (ftzy.com.cn) Net Profit

Corporate emblem and logo of Pheton Holdings Ltd (PTHL)

Risks depend on Chinese government funding and regulation. Pheton Holdings Ltd (PTHL) focuses primarily on precision radiation therapy planning software, which optimizes clinic resources. The company's actual profit confirms these trends, with the current metric equal to -0.00. Simultaneously, the business is restructuring its Asian component outsourcing to reduce costs and improve supply chains.

PTHL (ftzy.com.cn) Company Net Income history from 09/06/2024 to 01/16/2026

Financial and market metric breakdowns for ftzy.com.cn (PTHL)

- price and consensus price forecast:
Stock Quotes Pheton Holdings|PTHL - Analyst Consensus Forecast
- business market valuation indicators:
Market Capitalization PTHL|PTHL - Real Price to Acquire Entire Company
- book capitalization data:
Accounting Value of a Share Pheton Holdings|PTHL - Company Book Value|Market-to-Book Ratio ftzy.com.cn|PTHL - Cumulative Company Assets
- debt and solvency information:
Aggregate Debt to Capital Pheton Holdings Ltd|PTHL - Long-Term Debt to Capital|Ratio of Short-Term Indebtedness to Capital Pheton Holdings|PTHL - Company Aggregate Debts|Debts to Book Value PTHL|PTHL - Company Long-Term Debt|Company Short-Term Loans and Borrowings Pheton Holdings|Critical Liquidity Ratio ftzy.com.cn
- net income and valuation multiples indicators:
PTHL - Net Profit
Fundamental valuation:PTHL Pheton
Flagship merchandise of Pheton Holdings Limited

For radiotherapy software developer Pheton Holdings Ltd (PTHL), this indicator serves as a benchmark for the monetization efficiency of AI algorithms amid tight US monetary policy. By analyzing the company's bottom line, investors can see the net income remaining after all operating and credit expenses, which determines the business's resilience to cash flow gaps and confirms the quality of its expansion within the Chinese medtech market.

Main competitors

Net Income Haleon Corp|KVUE (Kenvue Inc.) - Net Profit|Net Profit veronapharma.com|Net Income MENS (Jyong Biotech)|LGND (Ligand Pharmaceuticals Incorporated) - Final Profit|Company Net Income Amneal Pharmaceuticals Inc AMRX|Perrigo Corp (PRGO) - Company Net Income|ALVO: Net Income|liquidia.com - Profit After Payment of Taxes|GLPG: Net Profit|ANI Pharmaceuticals Inc - Final Profit|MNKD (MannKind Corp.) - Net Profit|Company Net Income Amphastar Corp AMPH|Company Net Income Pacira BioSciences (PCRX)|SPRY (ars-pharma.com) - Final Profit|Company Net Income Theravance Biopharma, Inc. TBPH|AQST (Aquestive Therapeutics Inc) - Profit After Tax|scPharma - Net Profit|Final Profit TECX (Tectonic Therapeutic, Inc.)|TNXP: Net Profit|Company Net Income China SXT Pharmaceuticals, Inc. (SXTC)|Net Income EPRX|BHST (BioHarvest Sciences, Inc.) - Profit After Payment of Taxes|Company Net Income Invizyne Technologies, Inc. (EXOZ)|ORMP - Company Net Income|Company Net Income Entera Bio ENTX|HYFT: Company Profit|ABVC: Net Income|Final Profit CPIX (Cumberland Pharmaceuticals Inc)|QNTM: Net Profit|FibroGen Corporation - Final Profit|Company Net Income Telomir Pharmaceuticals|Company Net Income Rani Therapeutics Inc RANI|Company Net Income Synergy CHC Corp (SNYR)|Company Net Income RLYB (rallybio.com)|Net Profit LEXX (Lexaria Bioscience Corp.)|PULM: Company Profit|Aptorum - Net Profit|Net Financial Result lyratherapeutics.com LYRA|Impact BioMedical Inc (IBO) - Company Net Income|Company Profit TNFA|YCBD (cbdMD Inc.) - Net Profit|PRFX - Annual Net Income|Company Net Income Altamira Therapeutics (CYTO)|Net Financial Result lipella.com|OptiNose - Net Income|Final Profit PIRS|PROC - Company Net Income|PTPI: Company Net Income|QLI (Qilian International) - Net Income|SLRN: Profit After Payment of Taxes|TFFP (TFF Pharmaceuticals, Inc.) - Net Profit